Induction of HO-1; a Therapeutic Approach to Reduce Ischaemia Reperfusion Injury (IRI) Following Deceased Donor Renal Transplantation

• Status: Completed
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a blinded, placebo-controlled, randomised controlled trial looking at the effects of Heme arginate (HA) on cadaveric renal transplantation. The investigators know that HA can upregulate HO-1, which has been shown to have a protective effect on animal transplants.

The investigators will be giving HA/placebo to participants prior to transplant and repeat again on day 2 post-transplant and compare outcomes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Edinburgh
• Collaborator: NHS Lothian

Criteria

Inclusion Criteria:

• all patients receiving a cadaveric single kidney transplant

• patients on a standard immunosuppressive regime

Exclusion Criteria:

• patients on different immunosuppressives

• patients receiving 3rd or subsequent kidney transplant

• patients are fully anti-coagulated

• patients unable to take Heme Arginate

• patients unable to give informed consent

• patients on combined anti-platelet agents